What does BCL-2 do? From new molecular insights to the clinical implications

Area of Science:

• Cancer Biology
• Molecular Biology
• Immunology

Background:

• The BCL-2 protein family regulates apoptosis, a crucial process in cell death.
• Dysregulation of BCL-2 contributes to cancer pathogenesis, particularly in lymphoid malignancies.
• Mitochondrial Outer Membrane Permeabilization (MOMP) is a key event in apoptosis regulated by BCL-2.

Purpose of the Study:

• To review the journey from BCL-2 discovery to the development of clinical inhibitors.
• To discuss the mechanisms of BCL-2 in apoptosis regulation and its role in cancer.
• To explore challenges, resistance mechanisms, and future directions in BCL-2 targeted therapy.

Main Methods:

• Literature review of BCL-2 research, spanning basic science to clinical applications.
• Analysis of BCL-2 family interactions and their role in apoptosis.
• Examination of clinical data for BCL-2 inhibitors like venetoclax in hematological malignancies.

Main Results:

• BCL-2 inhibitors, such as venetoclax, have shown significant success in treating chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).
• Resistance to BCL-2 inhibitors can arise from BCL-2 mutations or upregulation of other anti-apoptotic proteins like MCL-1.
• Sublethal MOMP can trigger inflammatory responses, offering alternative therapeutic targets.

Conclusions:

• Targeting BCL-2 has transformed cancer therapy, particularly for hematological cancers.
• Overcoming resistance and expanding BCL-2 inhibitor efficacy to solid tumors remain significant challenges.
• Future research should focus on novel inhibitors, combination therapies, and understanding non-apoptotic roles of BCL-2.